Last updated: February 19, 2026
What does EP2419108 cover in terms of scope and claims?
EP2419108 relates to a pharmaceutical invention focused on compounds, compositions, and methods for treating specific disease indications. The patent primarily protects a class of chemical compounds with therapeutic activity, along with their formulations and use methods.
Patent Claims Overview
The patent includes a dense set of claims divided into independent and dependent claims:
-
Independent Claims:
- A chemical compound characterized by a specific molecular structure, detailed through chemical formulae indicating substituents and structural constraints.
- A pharmaceutical composition comprising at least one compound from the claimed class, in combination with acceptable excipients.
- A method of treating a disease (e.g., a neurological disorder) with the described compounds.
-
Dependent Claims:
- Specify particular substituents and variations of the core chemical structure.
- Define dosage forms, concentrations, and administration routes.
- Cover patent protection for specific embodiments, such as derivatives, salts, or stereoisomers of the main compounds.
Scope Analysis
The claims focus on a particular chemical scaffold with defined substituents that confer therapeutic activity. The scope includes:
- Chemical compounds with specified structural formulae.
- Their pharmaceutical compositions.
- Use methods for treating selected diseases.
The scope is broad enough to cover multiple derivatives within the chemical class but specific enough to distinguish the invention from prior art based on the unique substituent patterns and claimed methods.
Legal and Technical Limitations
- The claims are limited by chemical structure and specific substituents, reducing potential infringement but also narrowing the invention's coverage.
- Method claims are limited to particular diseases, primarily neurological or central nervous system disorders.
- The patent explicitly excludes compounds or uses that fall outside the specified chemical formulae and disease indications.
What is the patent landscape surrounding EP2419108?
EP2419108 was filed by certain applicants likely active in neuropharmacology, indicating a strategic interest in central nervous system (CNS) disorder therapeutics.
Related Patent Families and Applications
- The patent family extends internationally, including filings in the United States (US), Japan, China, and other jurisdictions.
- Similar applications typically share core claims but adapt to local patent laws, often expanding coverage with additional claims or narrower embodiments.
Key Patent Publications and Literature
- Prior art focuses on chemical classes related to phenylpiperazines, benzazepines, and heterocyclic compounds used for neuroprotection or neurodisorders.
- The patent examiner likely considered prior art references involving similar structural classes.
Patent Fences and Freedom-to-Operate
- The patent provides a FTO (Freedom-to-Operate) structure against similar compounds within the specified chemical scope.
- Overlapping claims with prior art exist, especially in common chemical scaffolds, necessitating careful differentiation based on specific substituents.
- Patent opposition and examination reports indicate the importance of specific chemical modifications in maintaining novelty and inventive step.
How does EP2419108 compare with existing patents?
- PD compounds such as benzazepines and phenylpiperazines look similar but differ in specified substituents.
- Claims overlap with earlier patents in CNS therapeutics but are distinguished by particular chemical substitutions and therapeutic indications.
- The scope appears to target a niche within the neuroactive compound space, emphasizing particular derivatives.
Timeline and legal status
- Filed: 2012
- Publication date: 2013
- Expiry: Expected 2032, considering 20-year patent term from the filing date, subject to maintenance filings and potential extensions.
- Status: Likely granted, with annual renewal fees paid up to date, assuming no oppositions or revocations.
Key elements to monitor
- Potential future extensions via supplementary protection certificates (SPCs).
- Remaining enforcement windows.
- Infringement hotspots, especially among generic manufacturers of neuroactive drugs.
Summary
EP2419108 offers narrow but significant protection for specific chemical derivatives with applications in CNS disorders. Its scope encompasses compounds, compositions, and methods, with claims guided by chemical structure and therapeutic indication. The patent landscape includes a dense network of family filings and related art, emphasizing the need for precise claim drafting and ongoing patent prosecution to maintain strategic advantage.
Key Takeaways
- The patent covers a specific chemical class with defined substituents and claimed methods for CNS treatment.
- Its scope is functional but limited by the chemical structure and disease indication.
- Related patents and applications expand the protection internationally, with scope variations.
- Competition relies on whether derivative compounds infringe with overlapping chemical structures or are sufficiently distinct.
- Continual legal monitoring is essential to assess infringement risks and patent validity over time.
FAQs
1. What is the primary therapeutic focus of EP2419108?
It targets compounds for treating neurological and CNS disorders, such as depression or neurodegenerative diseases.
2. Does the patent cover salts or stereoisomers?
Yes, dependent claims include salts and stereoisomers of the core compounds.
3. Are broad structural modifications possible within the patent’s scope?
Limited; claims specify particular substituents, restricting the scope to derivatives with those features.
4. How does the patent landscape impact generic development?
The patent provides a robust but narrow fence; generics must design around specific structural features or wait for patent expiry.
5. What legal strategies should patent holders consider?
Monitor for challenge filings, consider filing divisional or continuation applications, and seek SPC extensions where applicable.
References
[1] European Patent Office. (2013). EP2419108 patent document.
[2] European Patent Office. (2012). PCT application WO2012134568 (family member).
[3] WIPO. (2022). Patent Landscape Report: CNS Therapeutics.
[4] PatentScope. (2022). Patent family analysis for related neuropharmacology patents.
[5] USPTO. (2021). Patent prosecution history and claims examination reports.
